50 Key Veterinary Medicines with Estimated Sales, 2018 - 2022

• Leading companies in the animal health market were identified
• Annual reports, investor presentations, press releases, and product brochures of these companies were studied in detail. Information was also gleaned from paid databases such as Pitchbook.
• Blockbuster products and other leading revenue-generating products were identified along with segment revenues reported by the companies
• The data was plugged into our estimation models consisting of a hybrid approach (top down and bottom up) and variable analysis to derive products or molecule-specific revenues for consecutive years
• Some of the factors considered while estimating sales of veterinary medicines (pharmaceuticals, vaccines, medicated feed additives) include:
  • Product approvals
  • Regulatory landscape
  • Product usage and penetration
  • ASP
  • Patent analysis
  • Competition from generics

Scope

• Brand name
• INN (Active Ingredient Molecule)
• Molecular Weight
• First Approval/ Launch Year
• Indication
• Type
• Category
• Dosage Form
• Target Species
• Estimated Sales (USD million, 2018 to 2022)
• ASP (in USD)
• Commercialized/ Available in
• Patent/ Generics Information
• Other Notes

The above information would be provided for the following companies

• Boehringer Ingelheim International GmbH
• Elanco
• Virbac
• Zoetis